Search
revefenacin (Yupelri)
Indications:
- COPD
Contraindications:
- not for treatment of COPD exacerbation
Dosage:
- 175 ug (3 mL) via a standard jet nebulizer once daily
Adverse effects:
- cough, nasopharyngitis, upper respiratory tract infection
- headache, back pain
Drug interactions:
- concurrent use of rifampicin, cyclosporine
Mechanism of action:
- long-acting muscarinic receptor antagonist
Interactions
drug adverse effects of parasympatholytics
General
parasympatholytic (anticholinergic, antimuscarinic agent)
References
- Brooks M
FDA OKs Revefenacin (Yupelri) for COPD.
Medscape - Nov 09, 2018.
https://www.medscape.com/viewarticle/904710